<DOC>
	<DOCNO>NCT01147276</DOCNO>
	<brief_summary>The study examine whether DPP-4 inhibition vildagliptin affect glucagon counterregulatory response hypoglycemia type 1 diabetes .</brief_summary>
	<brief_title>Vildagliptin Glucagon Response Hypoglycemia Type 1 Diabetes</brief_title>
	<detailed_description>Vildagliptin ( 50 mg BID ) placebo give add-on insulin treatment four week patient type 1 diabetes . Then , hypoglycemic clamp ( 2.5 mmol/l glucose ) undertaken determination glucagon .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Type 1 diabetes Age &gt; 18 year HbA1c 6.58,5 % Pregnancy Lactation Acute infection Liver disease Treatment cortisol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>DPP-4</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Catecholamines</keyword>
	<keyword>Counterregulation</keyword>
	<keyword>Type 1 diabetes</keyword>
</DOC>